Deepika Pakianathan - Net Worth and Insider Trading

Deepika Pakianathan Net Worth

The estimated net worth of Deepika Pakianathan is at least $4 Million dollars as of 2024-04-25. Deepika Pakianathan is the Director of Karyopharm Therapeutics Inc and owns about 1,724,222 shares of Karyopharm Therapeutics Inc (KPTI) stock worth over $2 Million. Deepika Pakianathan is the Director of OncoMed Pharmaceuticals Inc and owns about 2,010,542 shares of OncoMed Pharmaceuticals Inc (OMED) stock worth over $2 Million. Deepika Pakianathan is also the Director of Calithera Biosciences Inc and owns about 0 shares of Calithera Biosciences Inc (CALA) stock worth over $0. Details can be seen in Deepika Pakianathan's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Deepika Pakianathan has not made any transactions after 2023-01-27 and currently still holds the listed stock(s).

Transaction Summary of Deepika Pakianathan

To

Deepika Pakianathan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Deepika Pakianathan owns 12 companies in total, including FS Development Corp () , Theravance Biopharma Inc () , and Calithera Biosciences Inc () among others .

Click here to see the complete history of Deepika Pakianathan’s form 4 insider trades.

Insider Ownership Summary of Deepika Pakianathan

Ticker Comapny Transaction Date Type of Owner
FS Development Corp 2020-08-11 director
Theravance Biopharma Inc 2020-07-01 director
Calithera Biosciences Inc 2023-01-27 director & 10 percent owner
Karyopharm Therapeutics Inc 2022-06-10 director
OncoMed Pharmaceuticals Inc 2019-04-23 director
Alder BioPharmaceuticals Inc 2018-05-23 director
Alexza Pharmaceuticals Inc 2016-06-21 director
Senseonics Holdings Inc 2016-03-17 10 percent owner
TriVascular Technologies Inc 2016-02-03 10 percent owner
Tandem Diabetes Care Inc 2013-11-13 10 percent owner
Disc Medicine Inc 2020-08-11 director
Pardes Biosciences Inc 2021-02-16 director

Deepika Pakianathan Latest Holdings Summary

Deepika Pakianathan currently owns a total of 3 stocks. Among these stocks, Deepika Pakianathan owns 1,724,222 shares of Karyopharm Therapeutics Inc (KPTI) as of June 10, 2022, with a value of $2 Million and a weighting of 50.88%. Deepika Pakianathan owns 2,010,542 shares of OncoMed Pharmaceuticals Inc (OMED) as of August 21, 2014, with a value of $2 Million and a weighting of 49.12%. Deepika Pakianathan also owns 0 shares of Calithera Biosciences Inc (CALA) as of January 27, 2023, with a value of $0 and a weighting of 0%.

Latest Holdings of Deepika Pakianathan

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KPTI Karyopharm Therapeutics Inc 2022-06-10 1,724,222 1.08 1,853,539
OMED OncoMed Pharmaceuticals Inc 2014-08-21 2,010,542 0.89 1,789,382
CALA Calithera Biosciences Inc 2023-01-27 0 0.02 0

Holding Weightings of Deepika Pakianathan


Deepika Pakianathan Form 4 Trading Tracker

According to the SEC Form 4 filings, Deepika Pakianathan has made a total of 1 transactions in Karyopharm Therapeutics Inc (KPTI) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Karyopharm Therapeutics Inc is the sale of 538,784 shares on June 10, 2022, which brought Deepika Pakianathan around $3 Million.

According to the SEC Form 4 filings, Deepika Pakianathan has made a total of 0 transactions in OncoMed Pharmaceuticals Inc (OMED) over the past 5 years. The most-recent trade in OncoMed Pharmaceuticals Inc is the acquisition of 80,203 shares on August 21, 2014, which cost Deepika Pakianathan around $2 Million.

According to the SEC Form 4 filings, Deepika Pakianathan has made a total of 1 transactions in Calithera Biosciences Inc (CALA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Calithera Biosciences Inc is the sale of 121,333 shares on January 27, 2023, which brought Deepika Pakianathan around $47,320.

Insider Trading History of Deepika Pakianathan

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Deepika Pakianathan Trading Performance

GuruFocus tracks the stock performance after each of Deepika Pakianathan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Deepika Pakianathan is 32.52%. GuruFocus also compares Deepika Pakianathan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Deepika Pakianathan within 3 months outperforms 3 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Deepika Pakianathan's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Deepika Pakianathan

Average Return

40.25%

Average return per transaction

Outperforming Transactions

50%

2 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 7.54 32.52 51.53 40.25 -19.92 -26.44
Relative Return to S&P 500(%) 6.81 28.94 44.08 29.38 -26.8 -34.08

Deepika Pakianathan Ownership Network

Ownership Network List of Deepika Pakianathan

No Data

Ownership Network Relation of Deepika Pakianathan


Deepika Pakianathan Owned Company Details

What does FS Development Corp do?

Who are the key executives at FS Development Corp?

Deepika Pakianathan is the director of FS Development Corp. Other key executives at FS Development Corp include director & 10 percent owner & President & CEO James B. Tananbaum , 10 percent owner Foresite Capital Fund V, L.p. , and 10 percent owner Foresite Capital Management V, Llc .

FS Development Corp () Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of FS Development Corp () in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of FS Development Corp () were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

FS Development Corp ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

FS Development Corp Insider Transactions

No Available Data

Deepika Pakianathan Mailing Address

Above is the net worth, insider trading, and ownership report for Deepika Pakianathan. You might contact Deepika Pakianathan via mailing address: 160 Bovet Road, Suite 408, C/o Delphi Ventures, San Mateo Ca 94402.

Discussions on Deepika Pakianathan

No discussions yet.